230 related articles for article (PubMed ID: 25136024)
1. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
Flanagan S; Fang E; Muñoz KA; Minassian SL; Prokocimer PG
Pharmacotherapy; 2014 Sep; 34(9):891-900. PubMed ID: 24989138
[TBL] [Abstract][Full Text] [Related]
4. Tedizolid population pharmacokinetics, exposure response, and target attainment.
Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
Bradley JS; Flanagan SD; Arrieta AC; Jacobs R; Capparelli E; Prokocimer P
Pediatr Infect Dis J; 2016 Jun; 35(6):628-33. PubMed ID: 26910588
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects.
Chen R; Shen K; Chang X; Tanaka T; Li L; Hu P
Clin Ther; 2016 Aug; 38(8):1869-79. PubMed ID: 27461846
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug.
Flanagan SD; Bien PA; Muñoz KA; Minassian SL; Prokocimer PG
Pharmacotherapy; 2014 Mar; 34(3):240-50. PubMed ID: 23926058
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.
Flanagan SD; Minassian SL; Prokocimer P
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):788-794. PubMed ID: 29319932
[TBL] [Abstract][Full Text] [Related]
9. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.
Lodise TP; Bidell MR; Flanagan SD; Zasowski EJ; Minassian SL; Prokocimer P
J Antimicrob Chemother; 2016 Sep; 71(9):2553-8. PubMed ID: 27317442
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age.
Arrieta AC; Ang JY; Espinosa C; Fofanov O; Tøndel C; Chou MZ; De Anda CS; Kim JY; Li D; Sabato P; Sears PS; Bradley JS
Pediatr Infect Dis J; 2021 Apr; 40(4):317-323. PubMed ID: 33710976
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.
Housman ST; Pope JS; Russomanno J; Salerno E; Shore E; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2012 May; 56(5):2627-34. PubMed ID: 22330925
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults.
Pai MP
Antimicrob Agents Chemother; 2016 Aug; 60(8):4585-9. PubMed ID: 27185808
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
15. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers.
Sahre M; Sabarinath S; Grant M; Seubert C; Deanda C; Prokocimer P; Derendorf H
Int J Antimicrob Agents; 2012 Jul; 40(1):51-4. PubMed ID: 22584101
[TBL] [Abstract][Full Text] [Related]
16. Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study.
Flanagan S; Litwin J; Fang E; Prokocimer P
Int J Antimicrob Agents; 2016 Jul; 48(1):33-40. PubMed ID: 27342387
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
Lepak AJ; Marchillo K; Pichereau S; Craig WA; Andes DR
Antimicrob Agents Chemother; 2012 Nov; 56(11):5916-22. PubMed ID: 22964254
[TBL] [Abstract][Full Text] [Related]
18. Reduction in Tedizolid Plasma Exposure among End-Stage Renal Disease Patients Undergoing Dialysis Is Explained by Variations in Ideal Body Weight.
Flanagan S; Prokocimer P
Antimicrob Agents Chemother; 2016 May; 60(5):3246-7. PubMed ID: 26926636
[No Abstract] [Full Text] [Related]
19. The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Sobue S; Tan K; Haug-Pihale G
Br J Clin Pharmacol; 2005 Feb; 59(2):160-6. PubMed ID: 15676037
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.
Ortiz-Covarrubias A; Fang E; Prokocimer PG; Flanagan SD; Zhu X; Cabré-Márquez JF; Tanaka T; Passarell J; Fiedler-Kelly J; Nannini EC
Braz J Infect Dis; 2016; 20(2):184-92. PubMed ID: 26859064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
